Zobrazeno 1 - 10 of 729 pro vyhledávání: '"Tick L"'
1
Akademický článek
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
Autor: Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T., van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., Levin, Mark-David
Publikováno v: In Blood 28 September 2023 142(13):1131-1142
Zobrazit plný text záznamu
2
Akademický článek
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Autor: Huls G; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands. g.huls@umcg.nl., Chitu DA; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands.; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Tick L; Department of Hematology, Maxima Medical Center, Veldhoven, The Netherlands., Boersma R; Department of Hematology, Amphia Hospital, Breda, The Netherlands., Breems D; Department of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium., Herbers A; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Klein SK; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands.; Department of Hematology, Meander Hospital Amersfoort, Amersfoort, The Netherlands., de Jonge S; Department of Hematology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Westerweel PE; Department of Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Cruijsen M; Department of Hematology, Catharine Hospital, Eindhoven, The Netherlands., Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Cuijpers M; Department of Hematology, Rijnstate Hospital, Arnhem, The Netherlands., Deeren D; Department of Hematology, AZ Delta Roeselare, Roeselare, Belgium., Bailly B; Department of Hematology, Hopital de Jolimont, Haine-Saint-Paul, Belgium., Visser O; Department of Hematology, Isala Hospital, Zwolle, The Netherlands., van Rhenen A; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands., Posthuma EFM; Department of Hematology, Reinier de Graaf Hospital, Delft, The Netherlands., Valk PJM; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Cloos J; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Ammatuna E; Department of Hematology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands., Refos JM; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands., Fakkert R; Department of Hematology, Hemato Oncology Foundation for Adults in the Netherlands, Rotterdam, The Netherlands., Löwenberg B; Department of Hematology, Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Publikováno v: Annals of hematology [Ann Hematol] 2024 Oct 05. Date of Electronic Publication: 2024 Oct 05.
Zobrazit plný text záznamu
3
Akademický článek
Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Mourits MP,* van kempen-harteveld ML, garcia MBG, koppeschaar HPF, tick L, terwee CB. Lancet 2000;355:1505-1509
Publikováno v: American journal of ophthalmology [Am J Ophthalmol] 2000 Sep; Vol. 130 (3), pp. 382.
Zobrazit plný text záznamu
5
Akademický článek
HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.
Autor: Minnema MC; Department of Hematology UMC Utrecht University Utrecht Utrecht The Netherlands., Nasserinejad K; Department of Hematology HOVON Data Center Erasmus MC Cancer Institute Rotterdam The Netherlands., Hegenbart U; Department of Hematology and Oncology Amyloidosis Center University Hospital Heidelberg Heidelberg The Netherlands., Ypma PF; Department of Internal Medicine Haga Hospital Den Haag The Netherlands., Wu KL; Department of Hematology Ziekenhuis Netwerk Antwerpen Stuivenberg Antwerp Belgium., Kersten MJ; Department of Hematology Amsterdam University Medical Center Amsterdam The Netherlands., Croockewit S; Department of Hematology Radboud University Medical Center Nijmegen The Netherlands., Zweegman S; Department of Hematology Amsterdam University Medical Center Amsterdam The Netherlands., Tick L; Department of Internal Medicine Máxima Medical Center Eindhoven The Netherlands., Broijl A; Department of Hematology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands., Koene H; Department of Internal Medicine Antonius Ziekenhuis Nieuwegein The Netherlands., Bos GMJ; Department of Internal Medicine Division of Hematology Maastricht University Medical Center+ Maastricht The Netherlands., Sonneveld P; Department of Hematology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands., Schönland SO; Department of Hematology and Oncology Amyloidosis Center University Hospital Heidelberg Heidelberg The Netherlands.
Publikováno v: EJHaem [EJHaem] 2024 Jun 17; Vol. 5 (4), pp. 815-819. Date of Electronic Publication: 2024 Jun 17 (Print Publication: 2024).
Zobrazit plný text záznamu
6
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
Autor: Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y, Ossenkoppele, G J
Publikováno v: Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y & Ossenkoppele, G J 2022, ' Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome ', Leukemia, vol. 36, no. 9, pp. 2189-2195 . https://doi.org/10.1038/s41375-022-01657-3
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group
Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287a701a807a9162ad042541d5d386bd
http://www.scopus.com/inward/record.url?scp=85134692962&partnerID=8YFLogxK
Zobrazit plný text záznamu
7
Akademický článek
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Autor: Herling M; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.; Department of Hematology, Cell Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany., Dearden C; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Zaja F; UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.; DSM University of Trieste, Trieste, Italy., El-Sharkawi D; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Ding W; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., Bellido M; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Khot A; Department of Clinical Haematology, Peter MacCallum Cancer Center, The Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia., Tick L; Department of Internal Medicine, Máxima Medical Center, Eindhoven, The Netherlands., Jacobsen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Eyre TA; Oxford Cancer & Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Roos-Weil D; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service Hematologie Clinique, Hopital Pitie Salpetriere, Paris, France., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Lucchini E; UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy., Pflug N; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Pena G; Department of Global Medical Affairs, Oncology, AbbVie, North Chicago, IL., Mukherjee N; Department of GSMD-Statistics, AbbVie, North Chicago, IL., Badawi M; Department of CPPM Clinical PK/PD, AbbVie, North Chicago, IL., Vizkelety T; Department of Global Medical Affairs, Oncology, AbbVie, North Chicago, IL., Staber PB; Universitaetsklinik fuer Innere Medizin I, Klinische Abteilung fuer Haematologie und Haemostaseologie, Medizinische Universitaet Wien, Vienna, Austria.
Publikováno v: Blood advances [Blood Adv] 2024 Feb 27; Vol. 8 (4), pp. 842-845.
Zobrazit plný text záznamu
8
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)
Autor: Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B. T., Graux, C., Huls, G., Janssen, J. J.J.W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., Van der Klift, M., Van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W.M., Van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J.F.M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Giovanni, San, Stuessi, Georg, Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M. G., van de Loosdrecht, A., Janssen, J. J.W.M., van Esser, J. W.J., Brouwer, R. E., Van Lammeren-Venema, D., Levin, M. D., Tick, L. W., Legdeur, M. C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J. H., von dem Borne, P. A., Schouten, H. C., Cornelissen, J., Wouters, B., Raaijmakers, H. G.M., Kuball, J.
Publikováno v: Leukemia, 34(10). Nature Publishing Group
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4231d8d48f8da424335ae95804aeb6bc
https://research.vumc.nl/en/publications/05f113e6-d597-4250-99cf-855010361d8a
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Autor: Ossenkoppele, G.J., Breems, D.A., Stuessi, G., Norden, Y. van, Bargetzi, M., Biemond, B.J., Borne, P.A. von dem, Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J.J.J.W., Jaspers, A., Jongen-Lavrencic, M., Jongh, E. de, Klein, S.K., Klift, M. van der, Kooy, M.V., Maertens, J., Micheaux, L., Poel, M.W.M. van der, Rhenen, A. van, Tick, L., Valk, P., Vekemans, M.C., Velden, W.J.F.M. van der, Weerdt, O. de, Pabst, T., Manz, M., Lowenberg, B., Havelange, Moors, I., Obberg, F. van, Maertens, J.A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Gjertsen, B.T., Passweg, J., Heim, D., Giovanni, S., Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M.G., Loosdrecht, A. van de, Janssen, J.J.W.M., Esser, J.W.J. van, Brouwer, R.E., Lammeren-Venema, D. van, Levin, M.D., Tick, L.W., Legdeur, M.C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J.H., Schouten, H.C., Cornelissen, J., Wouters, B., Raaijmakers, H.G.M., Kuball, J., Dutch-Belgian Hemato-Oncology, Swiss Grp Clinical Canc Res SAKK
Publikováno v: Leukemia, 1751-1759. Nature Publishing Group
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
Contains fulltext : 225470.pdf (Publisher’s version ) (Closed access) More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6afe4ddcbc8dbf30e80f1d9702e382d
https://research.rug.nl/en/publications/97f14b84-038f-45e9-8e79-0af373ddcd22
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje